High-Throughput Sequencing-Based Analysis of Changes in the Vaginal Microbiome during the Disease Course of Patients with Bacterial Vaginosis: A Case–Control Study

Simple Summary Because of their complexity, bacterial communities characteristic of bacterial vaginoses (BV) have not been completely characterized yet. The aim of the present study was to evaluate the changes in different characteristic bacteria during the onset, progression, and remission of BV. We performed a case–control study to investigate the differences in vaginal microbiota during the onset and post-treatment asymptomatic stages of BV. Participants were divided into four groups. We collected vaginal swabs and sequenced the V3–V4 hypervariable regions of bacterial 16S rRNA genes using the Illumina MiSeq platform. The sequencing results were used to evaluate vaginal microbiomes in the four groups. We observed significant differences in the composition and alpha diversity of the vaginal microbiota at different stages of BV, as well as in the distribution of bacterial communities among the investigated groups. We commented on these results and proposed future research directions. We believe that our study makes a significant contribution to the literature because it provides a basis for the screening of possible specific markers of BV, as well as for the prevention, diagnosis, treatment, and efficient monitoring of the disease in clinical practice. Abstract Background: The vaginal microbiome is closely associated with the onset and recurrence of bacterial vaginosis (BV). In the present study, the state of vaginal microbiota during the onset and post-treatment asymptomatic stages of BV were compared to that of a healthy population to evaluate the changes in different characteristic bacteria during the onset, progression, and remission of BV. Methods: A case–control study was performed to explore these changes. Women with clinical symptoms of BV were divided into the disease group (M) and case–control group (C) based on the Nugent score. Subjects in the disease group whose symptoms were resolved after the treatment were assigned to the treated group (T) and healthy subjects were recruited into the normal control (N) group. The V3–V4 hypervariable regions of bacterial 16S rRNA genes were sequenced on the Illumina MiSeq platform. Results: The N harbored the highest number of detected species and a higher abundance of microbiota; they had a significantly higher abundance of Lactobacillus and different bacterial community composition compared to the other three groups. In group M, Gardnerella vaginalis was the dominant species, whereas Lactobacillus iners was predominant in the other three groups. While Lactobacillus was more commonly present in Group C compared to group M. it was significantly increased in group T. Alpha diversity analysis of bacterial communities revealed significant differences in community richness and diversity among all four groups (p < 0.05). Significant differences in the distribution of various bacterial communities among the different groups were also observed (p < 0.05). Specifically, the abundance of eight bacterial taxa (Megasphaera, Aerococcus christensenii, Clostridiales, Gardnerella, Peptostreptococcus, Veillonellaceae, Akkermansia, Coriobacteriales) differed significantly among the four groups (p < 0.05). Conclusion: Significant differences in the composition and alpha diversity of the vaginal microbiota at different stages of BV and the distribution of bacterial communities were observed among the investigated groups. In addition to Gardnerella, Sneathia sanguinegens and Prevotella timonensis play an important role in the pathogenesis of BV. The appearance of BV-like clinical symptoms was closely associated with the decrease in Prevotella and Atopobium vaginae populations.

[1]  R. Burk,et al.  molBV reveals immune landscape of bacterial vaginosis and predicts human papillomavirus infection natural history , 2022, Nature communications.

[2]  F. Fenollar,et al.  Bacterial Vaginosis: What Do We Currently Know? , 2022, Frontiers in Cellular and Infection Microbiology.

[3]  H. Verstraelen,et al.  The Vaginal Microbiome: II. Vaginal Dysbiotic Conditions , 2021, Journal of Lower Genital Tract Disease.

[4]  Zongxin Ling,et al.  Contribution of Lactobacillus iners to Vaginal Health and Diseases: A Systematic Review , 2021, Frontiers in Cellular and Infection Microbiology.

[5]  Varun Sharma,et al.  An Insight into Vaginal Microbiome Techniques , 2021, Life.

[6]  C. Shen,et al.  Vaginal pH Value for Clinical Diagnosis and Treatment of Common Vaginitis , 2021, Diagnostics.

[7]  S. Garland,et al.  A Prospective, Open-Label Pilot Study of Concurrent Male Partner Treatment for Bacterial Vaginosis , 2021, mBio.

[8]  Yue Han,et al.  Does probiotics work for bacterial vaginosis and vulvovaginal candidiasis. , 2021, Current opinion in pharmacology.

[9]  J. Sobel,et al.  Bacterial vaginosis: drivers of recurrence and challenges and opportunities in partner treatment , 2021, BMC Medicine.

[10]  Yisheng Chen,et al.  Characterization of Vaginal Microbiota in Women With Recurrent Spontaneous Abortion That Can Be Modified by Drug Treatment , 2021, Frontiers in Cellular and Infection Microbiology.

[11]  Phillip R. Bennett,et al.  The reproductive tract microbiota in pregnancy , 2021, Bioscience reports.

[12]  Yiheng Liang,et al.  Probiotic Lacticaseibacillus rhamnosus GR-1 and Limosilactobacillus reuteri RC-14 as an Adjunctive Treatment for Bacterial Vaginosis Do Not Increase the Cure Rate in a Chinese Cohort: A Prospective, Parallel‐Group, Randomized, Controlled Study , 2021, Frontiers in Cellular and Infection Microbiology.

[13]  Tao Chen,et al.  The Female Vaginal Microbiome in Health and Bacterial Vaginosis , 2021, Frontiers in Cellular and Infection Microbiology.

[14]  R. Romero,et al.  Sneathia: an emerging pathogen in female reproductive disease and adverse perinatal outcomes , 2021, Critical reviews in microbiology.

[15]  V. Azevedo,et al.  Novel insights in bacterial vaginosis etiology through genomic approaches. , 2021, Anais da Academia Brasileira de Ciencias.

[16]  J. Thornton,et al.  A novel non-antimicrobial treatment of bacterial vaginosis: An open label two-private centre study. , 2020, European journal of obstetrics, gynecology, and reproductive biology.

[17]  J. Kaldor,et al.  Treating male partners of women with bacterial vaginosis (StepUp): a protocol for a randomised controlled trial to assess the clinical effectiveness of male partner treatment for reducing the risk of BV recurrence , 2020, BMC Infectious Diseases.

[18]  G. Bonaccorsi,et al.  Vaginal Microbiota and Cytokine Microenvironment in HPV Clearance/Persistence in Women Surgically Treated for Cervical Intraepithelial Neoplasia: An Observational Prospective Study , 2020, Frontiers in Cellular and Infection Microbiology.

[19]  J. Ravel,et al.  Bacterial Vaginosis and Its Association with Infertility, Endometritis, and Pelvic Inflammatory Disease. , 2020, American journal of obstetrics and gynecology.

[20]  M. Redelinghuys,et al.  Bacterial Vaginosis: Current Diagnostic Avenues and Future Opportunities , 2020, Frontiers in Cellular and Infection Microbiology.

[21]  R. Bagga,et al.  Genital Micro-Organisms in Pregnancy , 2020, Frontiers in Public Health.

[22]  R. Froissart,et al.  Exploring potential of vaginal Lactobacillus isolates from South African women for enhancing treatment for bacterial vaginosis , 2020, PLoS pathogens.

[23]  Michael R. Wierzbicki,et al.  Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. , 2020, The New England journal of medicine.

[24]  N. Gilbert,et al.  Gardnerella vaginalis as a Cause of Bacterial Vaginosis: Appraisal of the Evidence From in vivo Models , 2020, Frontiers in Cellular and Infection Microbiology.

[25]  P. Kardas,et al.  A Narrative Review of Current Challenges in the Diagnosis and Management of Bacterial Vaginosis , 2020, Sexually transmitted diseases.

[26]  F. Superti,et al.  Warding Off Recurrent Yeast and Bacterial Vaginal Infections: Lactoferrin and Lactobacilli , 2020, Microorganisms.

[27]  P. Madhivanan,et al.  Bacterial vaginosis-A brief synopsis of the literature. , 2019, European journal of obstetrics, gynecology, and reproductive biology.

[28]  J. Schwebke,et al.  Host-vaginal microbiota interactions in the pathogenesis of bacterial vaginosis. , 2019, Current opinion in infectious diseases.

[29]  Yingjie Zheng,et al.  Probiotics for the Treatment of Bacterial Vaginosis: A Meta-Analysis , 2019, International journal of environmental research and public health.

[30]  Christopher M. Taylor,et al.  An Updated Conceptual Model on the Pathogenesis of Bacterial Vaginosis. , 2019, The Journal of infectious diseases.

[31]  Zhi-Luo Deng,et al.  Treatment of biofilms in bacterial vaginosis by an amphoteric tenside pessary-clinical study and microbiota analysis , 2017, Microbiome.

[32]  J. M. Larsen The immune response to Prevotella bacteria in chronic inflammatory disease. , 2017, Immunology.

[33]  D. Eschenbach,et al.  [Bacterial vaginosis]. , 1985, Archives of gynecology.